humanized glp-1 receptor knock-in mouse Chronic treatment with glucagon-like peptide-1 and glucagon co- agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity Enhanced plasma half-life and efficacy

Most of these employers reported that this led to increased spending, leading some to indicate they will not cover these drugs in the future

Its oral small-molecule design improves accessibility and patient compliance compared to injectables

This putative mechanism shares similarities with metformin, the first-line medication for type 2 diabetes, rather than with incretin-based therapies

Whether you're on a GLP-1 medication and want complementary support, or you're taking the natural route entirely, this patch was made for you

Ozempic requires only weekly injections, making it a convenient and patient-friendly option compared to daily injections required by treatments such as Saxenda

Ozempic rose from a 10 th place ranking among the 10 top-selling Part D drugs in 2021, with gross spending of $2.6 billion, to 6 th place in 2022, with spending of $4.6 billion (Figure 2)